Heterogeneous transformation is not only the major clinical feature of prostate cancer, but also the main factor affecting therapeutic outcome. It is of great importance for the study of prostate cancer to establish patient-derived tumor xenograft ( PDX) transformation models. In this paper, we discuss the clinical heterogeneity of prostate cancer, review research progress in PDX models simulating clinical features, and focus on the urgently needed heterogeneous transformation model. We describe the ideal animal model needed for the study of prostate cancer transformation mechanisms and targeted drug screening.